Ampio Pharma Allowed To Extend Mid-stage Study Of Ampion In Covid-19 To India

(RTTNews) - Ampio Pharmaceuticals (AMPE) Tuesday said it has received approval from the FDA to expand enrollment of the mid-stage study of its lead drug Ampion in Covid-19 to India.

The phase II study of inhaled Ampion, dubbed AP-019, has been initiated following strong top-line results from the phase I study, the company said.

"Currently, India is reporting an average of more than 3,200 daily deaths from COVID-19 and over 94,000 new cases per day. We expect this expansion to shorten the timeline for overall study enrollment and potentially assist one of the world's highest density populations of COVID-19 infections," said Michael Macaluso, President and CEO of Ampio.